

February 10, 2021

To,
The Manager
Listing Department,
The National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai – 400051

Dear Sir/ Madam,

Trading Symbol: ZOTA

Sub: Outcome of Board Meeting held on Wednesday, February 10, 2021

Ref.: Regulation 30 & 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to the captioned subject, we Zota Health Care Limited (the "Company") would like to inform you that the Board of Directors of the Company in its Meeting held on Wednesday, February 10, 2021 at 02:00 P.M. at the registered office of the Company situated at Zota House, 2/896, Hira Modi Street, Sagrampura, Surat — 395002, Gujarat, have *inter alia*, discussed and approved the following business:

1. Considered and approved the Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2020 along with Limited Review Reports thereon. Financial Results and Limited Review Reports are enclosed herewith (Annexure – I).

Unaudited standalone and consolidated financial results for the period as aforementioned shall be available on the website of the Stock Exchange where the shares of the Company are listed i.e. at www.rseindia.com and on Company's website at www.zotahealthcare.com

The Board meeting concluded at 5:10 P.M.

This is for your information and record.

Thanking you,

Yours faithfully,

For Zóta Health Care Limited

Ashvin Variva

(Company Secretary & Compliance Officer)

Place: Surat


Encl: a/a

Registered Office:

Zota House, 2/896, Hira Modi Street, Sagrampura, Surat - 395 002 | Ph: +91 261 2331601 Email: info@zotahealthcare.com Web: www.zotahealthcare.com Plant:

Plot no. 169, Surat Special Economic Zone, Nr. Sachin Railway Station, Sachin, Surat - 394 230 (Guj.) India Ph: +91 261 2397122

CIN: L24231GJ2000PLC038352



CHARTERED ACCOUNTANTS

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
The Board of Directors of
Zota Health Care Limited

We have reviewed the accompanying statement of Standalone Unaudited Financial Results of **Zota Health Care Limited** (the "Company") **for the quarter and nine months ended December 31, 2020** ("the Statement") attached herewith, being submitted by the Company pursuant to requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time.

Management's Responsibility

This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

Auditor's Responsibility

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Conclusion

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing

302, SAI BHAVAN, NR. NEW SAIBABA TEMPLE, OPP. SMC MULTILEVEL PARKING, SHAHPORE,

SURAT-395002.



CHARTERED ACCOUNTANTS

Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Date: 10/02/2021 Place: Surat SURAT SURAT

For Shivangi Parekh & Co. Chartered Accountants ICAI FRN: 131449W

> CA. Shivangi Mehta Proprietor M. No.118936

UDIN: 21118936AAAAAA46664



ZOTA HEALTH CARE LIMITED

Unaudited Standalone Financial Results for the Quarter and Nine Months ended 31st December, 2020

(₹ in Lakhs, except per share data) Quarter Ended Nine Months Ended Year Ended **Particulars** 31-12-2020 30-09-2020 31-12-2019 31-12-2020 31-12-2019 31-03-2020 (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Audited) Revenue from Operations 3048.27 2816.64 2506.38 7619.86 7203.31 9511.27 II. Other Incomes 57.09 21.14 30.74 101.04 98.04 151.30 III. Total Revenue 3105.35 2837.78 7720.90 2537.11 7301.35 9662.57 Expenses: IV. Cost of Materials Consumed: 792.23 348.78 430.07 1364.46 972.23 1303.92 Purchases of Stock-in-Trade 1275.06 1708.73 1069.13 4666.51 3567.99 4617.40 Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade 73.06 (186.02) 287.15 (854.80) 540.48 708.70 Employee Benefit Expenses 231.66 236.81 263.00 674.97 765.50 1034.05 Finance Costs 3.42 1.48 2.31 5.65 4.63 6.91 Depreciation / Amortisation and Depletion Expense 80.08 76.63 48.08 230.62 209.75 110.16 Other Expenses 794 86 623.10 383.67 1686.91 1056.47 1393.81 **Total Expenses** 3250.36 2809.53 2483.41 7774.32 7017.46 9274.55 ٧. Profit before Exceptional items and tax from continuing operations (145.01) 28.25 53.71 (53.41)283.89 388.02 VI. Exceptional Items 102.88 102.88 VII Profit/(loss) before tax (145.01)131.13 53.71 49.47 283.89 388.02 VIII. Tax Expense: (1) Current tax (33.27)31.40 15.80 16.43 73.69 103.53 (1.1) I.T. & DD Tax Provision Created Short/ excess (7.59)(7.59) 0.26 2.07 (2) Deferred Tax 2.01 0.14 11.20 (6.62)(6.40)IX. Profit/ (Loss) for the period from Continuing Operations (VII-VIII) (100.76) 101.74 38.04 51.82 203.33 276.01 X. Profit/(loss) before tax from discontinued operations XI Tax Expense of discontinued Operations Profit/ (Loss) from Discontinued Operations (after Tax) XII. (X- XI) XIII. Profit/ (Loss) for the period (100.76) 101.74 38.04 51.82 203.33 276.01 XIV. Other Comprehensive Income A (i) Items that will not be reclassified to Statement of profit and loss (10.23) 14.68 0.97 16.27 16.46 (ii) Income Tax relating to items that will not be reclassified to Statement of profit and loss 2.58 (3.69) (0.05) (0.25)(4.09)(4.14) B (i) Items that will be reclassified to Statement of profit and loss (ii) Income Tax relating to items that will be reclassified to profit and loss Other comprehensive income for the period, net of tax (7.66) 10.98 0.13 0.73 12.18 12.32 Total comprehensive income for the period (XIII + XIV) (108.41) 112.72 38.18 52.55 288.33 Paid-up Equity Share Capital 2456.03 2456.03 2456.03 2456.03 2456.03 2456.03 Other Equity 4429.06 Earnings per equity share of face value of ' 10 each (1) Basic (in ') (0.41) 0.41 0.15 0.21 0.83 1.12 (2) Diluted (in ') (0.41)0.41 0.83 0.21

denotes figures less than a lakh For and on behalf of the Board

(Whole Time Director)

(Managing Director) Himanshu M. Zota Moxesh K. Zota (Din: 01097722) (Din: 07625219)

Chief Financial Officer pany Secretary Ashvin Variya Viral Mandviwala

Date: 10/02/2021 Place: Surat



Zota House, 2/896, Hira Modi Street, Sagrampura, Surat - 395 002 | Ph: +91 261 2331601 Email: info@zotahealthcare.com

Web: www.zotahealthcare.com

Plant:

Plot no. 169, Surat Special Economic Zone, Nr. Sachin Railway Station, Sachin, Surat - 394 230 (Guj.) India Ph: +91 261 2397122

Pare

Stento hivangi Mehta Proprietor M. No. 118936 Firm No. 131449W

For Shivangi Parekh & Co. **Chartered Accountants**

CIN: L24231GJ2000PLC038352

CHARTERED ACCOUNTANTS

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
The Board of Directors of
Zota Health Care Limited

We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **Zota Health Care Limited** ("the Parent") **and its subsidiaries** (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit/(loss) after tax and total comprehensive income / loss for the **quarter and nine months ended December 31, 2020** ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Regulation").

Management's Responsibility

This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

Auditor's Responsibility

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

The Statement includes the results of the following entities:

- a. Zota Health Care Limited (Parent)
- b. Zota Healthcare Lanka (Pvt.) Ltd. (Wholly Owned Subsidiary)

302, SAI BHAVAN, NR. NEW SAIBABA TEMPLE, OPP. SMC MULTILEVEL PARKING, SHAHPORE,

SURAT-395002.

CHARTERED ACCOUNTANTS

c. Davaindia Health Mart Limited (Wholly Owned Subsidiary)

Conclusion

Based on our review conducted and procedures performed as stated in paragraph 3, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Other Matters

We did not review the interim financial statements of the subsidiaries included in the consolidated unaudited financial results that reflect total revenues of Rs. 0.06 Lakhs and Rs.0.30 Lakhs, total net profit/(loss) after tax of Rs. (0.03) Lakhs and Rs. 0.14 Lakhs and total comprehensive income of Rs. (0.03) Lakhs and Rs. 0.14 Lakhs, respectively for the quarter and nine months ended December 31, 2020, as considered in the consolidated unaudited financial results. These interim financial statements have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the above matters.

Date: 10/02/2021

Place: Surat

For Shivangi Parekh & Co. Chartered Accountants ICAI FRN: 131449W

CA. Shivangi Mehta

Proprietor

M. No.118936

UDIN: 21118936 AAAAAN9698

SURAT



	healthcare itd.	Quarter Ended			(₹ in Lakhs, except Nine Months ended		Year Ended
	Particulars	31-12-2020 (Unaudited)	30-09-2020 (Unaudited)	31-12-2019 (Unaudited)	31-12-2020 (Unaudited)	31-12-19 (Unaudited)	31-03-2020 (Audited)
I.	Revenue from Operations	3048,27	2816.64	2506.38	7619.86	7203.31	9511,2
11.	Other Incomes	57.15	21.10	30.74	101.34	98.04	151.3
11.	Total Revenue	3105.42	2837.74	2537.11	7721.20	7301.35	
1.	Expenses:			2337.11	7721.20	/301.33	9662.5
	Cost of Materials Consumed:	792.23	240.70	420.07	100000000	August 150	
	Purchases of Stock-in-Trade	1275.06	348.78 1708.73	430.07 1069.13	1364.46	972.23	1303.9
	Changes in Inventories of Finished Goods, Work-in-Progress and Stock-	2275.00	1700.73	1009.13	4666.51	3567.99	4617.4
	in-Trade	73.06	(186.02)	287.15	(854.80)	540.48	708.7
	Employee Benefit Expenses	231.66	236.81	263.00	674.97	765.50	1034.0
	Finance Costs	3.42	1.48	2.31	5.65	4.64	6.9
	Depreciation / Amortisation and Depletion Expense	80.08	76.63	48.08	230.62	110.16	209.7
	Other Expenses	794.96	623.10	383.71	1687.07	1056.55	1395.6
	Total Expenses	3250.46	2809.53	2483.44	7774.47	7017.55	9276.4
-51	Profit before Exceptional items and tax from continuing operations		\$				
	(III-IV) **	(145.04)	28.22	53.68	(53.27)	283.80	386.1
	Exceptional Items		102.88	-	102.88	285.00	360.1
1.	Profit/(loss) before tax	(145.04)	131.10	53.68	49.61	283.80	386.1
I.	Tax Expense:	480 m240 200 00 00 00 00 00 00 00 00 00 00 00 0			15.02	203.00	360,1
	(1) Current tax	(33.27)	31.40	15.80	16.43	73.69	103.5
	(1.1) I.T. & DD Tax Provision Created Short/ excess (2) Deferred Tax	(7.59)		-	(7.59)	0.26	2.0
	(2) Deterred Tax	3.40	2.01	0.14	11.20	(6.62)	(6.4
	Profit/ (Loss) for the period from Continuing		1				
	Operations (VII-VIII)	(100.79)	101.71	38.01	51.96	203.24	274.1
	Profit/(loss) before tax from discontinued operations	5 5 []	1025	-	_	AP 1000 000 000 000 000 000 000 000 000 0	5-7/1000
	Tax Expense of discontinued Operations	26 13					
*:	Profit/ (Loss) from Discontinued Operations (after Tax)	~ 1	Stans		0.7.	-	
	(X- XI)		55-5		0.43	2	
	Profit/ (Loss) for the period	(100.79)	101.71	38.01	51.96	203.24	274.15
	Other Comprehensive Income A (I) Items that will not be reclassified to Statement of					203.24	274.1.
	profit and loss	(10.23)	14.68	0.10		9292923	0103321
	(ii) Income Tax relating to items that will not be	(10.23)	14.00	0.18	0.97	16.27	16.46
	reclassified to Statement of profit and loss B (i) Items that will be reclassified to Statement of profit	2.58	(3.69)	(0.05)	(0.25)	(4.09)	(4.14
	and loss	0.01	0.5	0.01			
	(ii) Income Tax relating to items that will be reclassified	0.01	1.7	0.01		(0.08)	
	to profit and loss	*	*	a .	*		
	Other comprehensive income for the period, net of tax	(7.65)	10.99	0.15	0.73	12.10	12.32
	Total comprehensive income for the period (XIII + XIV)	(108.44)	112.70	38.16	52.70	215.34	286.47
	Profit attributable to:					100000000	
	Owners of the parent	(100.79)	101.71	38.01	51.96	203.24	274.15
	Non-controlling interest	-	1				200.40
	Other comprehensive income attributable to:	200.00					
	Owners of the parent	(7.65)	10.99	0.15	0.73	12.10	12.32
	Non-controlling interest	120	0 + .	9	5#	-	
	Total Comprehensive Income attributable to:		Quantitative of the	4,0004004	grane and a		
	Owners of the parent Non-controlling interest	(108.44)	112.70	38.16	52.70	215.34	286.47
		157).=	-	2		
	Paid-up Equity Share Capital	2456.03	2456.03	2456.03	2456.03	2456.03	2456.03
	Other Equity		1				4426.87
	Earnings per equity share of face value of ` 10 each						
	(1) Basic (in ')	(0.41)	0.41	0.15	0.21	0.83	1.12
_	(2) Diluted (in `)	(0.41)	0.41	0.15	0.21	0.83	1.12

denotes figures less than a lakh For and on behalf of the Board

4.6n.28 (Whole Time Director) Himanshu M. Zota (Din: 01097722)

(Managing Director) Moxesh K. Zota (Din: 07625219)

Valvar Company Secretary Ashvin Variya

Chief Financial Officer Viral Mandviwala

Date: 10/02/2021 Place : Surat

Parex

For Shivangi Parekh & Co. **Chartered Accountants**

> CA. Shivangi Mehta Proprietor M. No. 118936 Firm No. 131449W

Registered Office:

Zota House, 2/896, Hira Modi Street, Sagrampura, Surat - 395 002 | Ph: +91 261 2331601 Email: info@zotahealthcare.com Web: www.zotahealthcare.com

Plant:

Plot no. 169, Surat Special Economic Zone, Nr. Sachin Railway Station, Sachin, Surat - 394 230 (Guj.) India Ph: +91 261 2397122

CIN: L24231GJ2000PLC038352



Notes:

- 1. The above financial results for the quarter and nine months ended December 31, 2020 have been reviewed and recommended by the Audit Committee and subsequently approved by the Board of Directors at their meeting held on February 10, 2021.
- The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder.
- 3. The Statutory Auditors have carried out Limited Review of the financial results for the quarter and nine months ended December 31, 2020.
- 4. The Company is continuously monitoring the impact of COVID-19 on Company's business. The Company has done assessment of its liquidity position and expects to fully recover the carrying amount of receivables, investments, intangible assets and other assets. The Company has also evaluated the inventory in hands and found it's sufficient to honor future orders.
- 5. During the Q2 FY21, the Company has sold the open industrial plot situated at Hojiwala Industrial Estate, Surat at the consideration of Rs. 108.42 lakhs. The said industrial plot was purchased back in the year 2004 for the purpose of establishment of warehouse/ factory. But due to non-viable circumstances it was not done. The said industrial plot remained unutilized since then. Profit on sale of the said plot has been reported under the head exceptional item in the Statement of profit and loss accounts of the Company for the nine months ended December 31, 2020.
- 6. The Company has evaluated its Operating segment in accordance with IND AS 108 and has concluded that it is engaged in a single operating segment.
- 7. The consolidated results include the result of following wholly owned subsidiaries:
 - Zota Healthcare Lanka (Pvt.) Ltd.
 - ii) Davaindia Health Mart Limited
- 8. The figures for the corresponding previous period have been regrouped/reclassified wherever necessary, to make them comparable.



Plant:

Plot no. 169, Surat Special Economic Zone, Nr. Sachin Railway Station, Sachin, Surat - 394 230 (Guj.) India Ph: +91 261 2397122

Registered Office:

Zota House, 2/896, Hira Modi Street, Sagrampura, Surat - 395 002 | Ph. +91 261 2331601 Email: info@zotahealthcare.com Web : www.zotahealthcare.com